Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
With the first wave of cancer immunotherapies continuing to show their potential to revolutionize treatment paradigms, major pharmaceutical companies are leaving no stone unturned in the search for winning combination therapies that harness immuno-oncology drugs.
InDanio Bioscience Inc.’s unique Ligand Trap system provides in vivo, high-content drug discovery for compounds targeting nuclear receptors and epigenetic regulators while allowing evaluation of toxicity, bioavailability and tissue selectivity.
Synaffix’s site-specific–conjugation and payload-enhancement technologies are improving the safety and efficacy of antibody-drug conjugates (ADCs) without the need for antibody engineering.
With the key goal of improving the outcomes for people with cancer, university-launched OncoTherapy Science, Inc. is developing a pipeline of small-molecule drugs and a number of therapeutic peptide vaccines.
With two established technologies, SLPs and AMPLIVANT, ISA Pharmaceuticals is developing fully synthetic immunotherapeutic vaccines to target cancer and persistent viral infections.
By targeting noncoding mitochondrial RNA with antisense oligonucleotide drugs, Andes Biotechnologies is developing potential cancer therapies capable of inducing inhibition of cell proliferation and apoptosis.
This Canadian biotechnology company is developing combination-treatment strategies based on monoclonal antibodies to improve clinical outcomes for cancer patients.